Advisor Group’s Stemline Therapeutics, Inc. STML Stock Holding History

Advisor Group’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$0	Sell	9 -1,200	-99%	-$11.9K	﹤0.01%	5560
2019 Q3	$13K	Hold	1,209	–	–	﹤0.01%	4223
2019 Q2	$19K	Hold	1,209	–	–	﹤0.01%	4022
2019 Q1	$16K	Buy	1,209 +1,000	+478%	+$11.3K	﹤0.01%	4115
2018 Q4	$2K	Hold	209	–	–	﹤0.01%	4881
2018 Q3	$3K	Buy	+209	New	+$3.35K	﹤0.01%	4791
2017 Q1	–	Sell	-2	Closed	–	–	4866
2016 Q4	$0	Hold	2	–	–	﹤0.01%	4709
2016 Q3	$0	Hold	2	–	–	﹤0.01%	4692
2016 Q2	$0	Buy	+2	New	+$13	﹤0.01%	4568

Other funds holding STML

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $128B AUM 35.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Advisor Group's STML Position: Q4 2019 in Review

Advisor Group reduced its Stemline Therapeutics, Inc. (STML) stake by 99% in Q4 2019, selling an estimated $11.9K and leaving 9 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5560.

Advisor Group first reported a position in STML in Q2 2016 and has held it in 9 quarters since. The position peaked at $19K in Q2 2019. 99 funds tracked by Wall St. Rank hold STML as of Q4 2019.

Advisor Group held 9 shares of Stemline Therapeutics, Inc. worth $0 as of Q4 2019.
Advisor Group sold 1,200 Stemline Therapeutics, Inc. shares in Q4 2019, an estimated $11.9K.
Stemline Therapeutics, Inc. made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #5560 holding.
Advisor Group first reported a position in Stemline Therapeutics, Inc. in Q2 2016 and has held it in 9 quarters since.
Advisor Group's Stemline Therapeutics, Inc. position peaked at $19K in Q2 2019.
99 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.